Oncology development

What monarchE Shows About Nodal Risk in Early Breast Cancer

See how tumor grade and size shape recurrence risk in the monarchE nodal analysis and what oncology sites can do to document screening decisions.

By Lampgen Clinical Research

Two clinical research professionals review a report beside the headline “The pathology behind high risk” and the words “Tumor grade. Tumor size. Positive nodes.”
Editorial illustration of oncology research staff reviewing a pathology record.
21.6%25.4%
Estimated six-year rates of an invasive disease-free survival event on endocrine therapy alone in the high-risk group with 1–3 positive nodes and the group with 4–9 positive nodes, respectively. [1]

What the source reported

One to three positive axillary lymph nodes can mark high-risk early breast cancer when the tumor is grade 3 or at least 5 cm. In the 2026 ESMO Open analysis of monarchE, the six-year risk of an invasive disease-free survival event on endocrine therapy alone in this group approached the rate for patients with four to nine positive nodes. The analysis helps explain why tumor grade and size belong alongside the node count when an oncology team discusses an existing adjuvant treatment option. [1, 4]

How the trial defined nodal risk

The phase 3 monarchE trial randomized 5,637 patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Patients received standard endocrine therapy with or without two years of adjuvant abemaciclib, a CDK4/6 inhibitor. The nodal report used data through July 15, 2025. At a median follow-up of 76.8 months, 5,107 of the 5,120 participants in cohort 1 were included in the three nodal subgroups. [1, 3, 6]

High-risk N1 included patients with one to three positive axillary nodes plus grade 3 disease, a tumor measuring at least 5 cm, or both. N2 included four to nine positive nodes. N3 included ten or more. The primary endpoint, invasive disease-free survival (IDFS), measures time to invasive recurrence, certain new invasive cancers, or death. [1]

How much the combination changed outcomes

On endocrine therapy alone, the estimated six-year IDFS event rate reached 38.1% in the N3 group. Adding abemaciclib increased estimated six-year IDFS by 4.6 percentage points in high-risk N1, 6.9 points in N2, and 8.1 points in N3. Distant recurrence-free survival also favored the combination across the three groups. The comparison between nodal groups is descriptive, and the benefit estimates apply to the populations studied. [1, 2]

A separate, planned analysis in the full randomized population found estimated seven-year overall survival of 86.8% with abemaciclib plus endocrine therapy and 85.0% with endocrine therapy alone. That was an absolute difference of 1.8 percentage points (hazard ratio 0.842, 95% confidence interval 0.722–0.981). Overall survival was a key secondary endpoint of the trial. [3]

What the results mean for adjuvant treatment discussions

The U.S. indication already includes high-risk, node-positive, HR-positive, HER2-negative early breast cancer. The FDA defines high risk as at least four positive pathologic axillary lymph nodes, or one to three with a grade 3 tumor or a tumor at least 5 cm. The FDA removed the Ki-67 testing requirement in March 2023. [4]

The benefit comes with a two-year course of added treatment. In the monarchE safety population, 19% of patients receiving abemaciclib permanently discontinued it because of adverse reactions. Diarrhea and neutropenia were common, and U.S. prescribing information calls for blood count and liver function monitoring. Discussing the absolute benefit alongside the early monitoring schedule, travel, and access to help with side effects gives patients a clearer picture of what treatment would involve. [5]

What this means for trial teams

Capture each eligibility criterion at screening. For a future protocol with similar rules, record the positive axillary node count, tumor size and units, and histologic grade as separate fields. Specify which pathology report the protocol accepts and who reconciles conflicting or amended records. The investigator confirms and documents the eligibility decision.

Track records from outside the health system. Consider a hypothetical referral with two positive nodes, a 2.8 cm tumor, and a grade pending from an outside lab. Grade 3 would meet the pathology criterion in a trial that uses the monarchE cohort 1 rule. Give the report request an owner and a due date. Review time spent waiting for records by site and referral source to see where eligible patients could lose time in a screening window.

Check whether the process works across sites. An oncology CRA can reconcile the screening record to the final report, flag discrepancies through the monitoring plan, and confirm that the investigator’s assessment is documented. The study manager can review recurring delays with sites and check whether the change reduced unresolved records. Lampgen Clinical Research helps sponsors and CROs staff oncology monitoring around these responsibilities. [7]

Sources

  1. Cortes et al., monarchE nodal subgroup analysis, ESMO Open, 2026
  2. Cortes et al., monarchE nodal subgroup results, SABCS 2025 abstract PS1-08-08
  3. Johnston et al., monarchE overall survival analysis, Annals of Oncology, 2026
  4. FDA, expanded early breast cancer indication for abemaciclib, March 2023
  5. DailyMed, Verzenio U.S. prescribing information
  6. ClinicalTrials.gov, monarchE trial record NCT03155997
  7. FDA, ICH E6(R3) Good Clinical Practice guidance
  8. Related Lampgen insight on why overall survival takes years to measure
  9. Related Lampgen insight on reviewing screen-failure logs

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?